Stock Code: 002932 Stock Abbreviation: Mindray Bio-Tech Announcement No.: 2026-058
Wuhan Mindray Bio-Tech Co., Ltd.
Announcement Regarding the Termination of Certain Fund-Raising Investment Projects and the Change of Use of Raised Funds
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or major omissions.
Wuhan Mindray Bio-Tech Co., Ltd. (hereinafter referred to as the "Company") held the ninth meeting of the fifth Board of Directors on July 31, 2026, and deliberated and approved the "Proposal on Terminating Certain Fund-Raising Investment Projects and Changing the Use of Raised Funds." The Company agreed to terminate the "Medical Health Information Project" and use the remaining raised funds, together with the accumulated financial management income and interest income from the special fund-raising account (the final amount shall be subject to the balance on the date of approval by the Company's shareholders' meeting), for the project of acquiring 100% equity of Wuhan Bicare Medical Rescue Supplies Co., Ltd. (hereinafter referred to as "Wuhan Bicare," "Bicare," or the "Target Company"). Any shortfall will be covered by the Company's own funds. This termination of certain fund-raising investment projects and the change in the use of raised funds do not constitute a related-party transaction and are still subject to the approval of the Company's shareholders' meeting. The relevant matters are announced as follows:
I. Basic Situation of Raised Funds
Approved by the "Reply on Approving the Non-public Issuance of Shares of Wuhan Mindray Bio-Tech Co., Ltd." (Zheng Jian Xu Ke [2021] No. 1859) issued by the China Securities Regulatory Commission, the Company non-publicly issued 8,259,846 RMB ordinary shares (A shares). The total amount of raised funds was 466,103,109.78 RMB. After deducting issuance expenses of 6,261,109.77 RMB, the actual net proceeds were 459,842,000.01 RMB. The above-mentioned raised funds have all been deposited in the special fund-raising account for management and have been verified by Lixin Certified Public Accountants (Special General Partnership), which issued the "Capital Verification Report" (Xin Hui Shi Bao Zi [2021] No. ZE10585).
II. Use of Raised Funds
As of June 30, 2026, the specific usage of the Company's raised funds is as follows:
Unit: 10,000 RMB
| Project | Committed Investment Amount | Adjusted Total Investment | Accumulated Investment | Investment Progress | Account Balance (Including Interest) |
|---|---|---|---|---|---|
| In vitro diagnostic product construction project | 20,410.65 | 21,522.74 | 16,054.03 | 74.59% | 7,316.73 |
| Medical health information project | 12,073.55 | 12,073.55 | 2,052.91 | 17.00% | 10,984.09 |
| Supplementary working capital | 13,500.00 | 13,500.00 | 13,500.00 | 100.00% | 0.00 |
| Total | 45,984.20 | 47,096.29 | 31,606.94 | 67.11% | 18,300.82 |
III. Relevant Situation and Reasons for Terminating Certain Fund-Raising Projects and Changing the Use of Raised Funds
(I) Situation of Changing the Use of Raised Funds
In order to improve the efficiency of the use of raised funds and combine changes in the policy environment with corporate development needs, the Company intends to terminate the "Medical Health Information Project" and change its purpose. The Company will use all raised funds for this project, amounting to 100.2064 million RMB, and the interest accrued as of the date of this announcement, 9.6345 million RMB (the final amount shall be subject to the balance on the date of approval by the Company's shareholders' meeting), to acquire 100% equity of Wuhan Bicare. The situation after the change of the non-public offering fund-raising project is as follows:
| Project | Pre-change Proposed Investment | Investment Change | Post-change Proposed Investment | Change Explanation |
|---|---|---|---|---|
| In vitro diagnostic product construction project | 21,522.74 | - | 21,522.74 | |
| Medical health information project | 12,073.55 | -10,020.64 | 2,052.91 | Terminated and changed |
| Supplementary working capital | 13,500.00 | - | 13,500.00 | |
| Acquisition of 100% equity of Wuhan Bicare | - | 10,020.64 | 10,020.64 | New project |
| Total | 47,096.29 | - | 47,096.29 |